Nerandomilast (Jascayd) approved to treat adult patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
As with any medicinal product, the MHRA will keep the safety and effectiveness of nerandomilast under close review.
As with any medicinal product, the MHRA will keep the safety and effectiveness of nerandomilast under close review.